Vital Therapies, Inc. (NASDAQ:VTL) Director Jean Jacques Bienaime acquired 10,000 shares of the stock in a transaction on Wednesday, September 13th. The shares were acquired at an average price of $4.00 per share, with a total value of $40,000.00. Following the transaction, the director now directly owns 65,119 shares of the company’s stock, valued at $260,476. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Shares of Vital Therapies, Inc. (VTL) traded up 5.88% during midday trading on Friday, hitting $4.50. 587,555 shares of the stock traded hands. The stock’s market cap is $189.93 million. The company’s 50 day moving average price is $3.06 and its 200-day moving average price is $3.36. Vital Therapies, Inc. has a 12-month low of $2.25 and a 12-month high of $6.58.

Vital Therapies (NASDAQ:VTL) last announced its quarterly earnings results on Thursday, August 3rd. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.01. During the same quarter last year, the firm posted ($0.30) EPS. On average, equities research analysts expect that Vital Therapies, Inc. will post ($1.31) EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was stolen and republished in violation of US & international copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/09/16/jean-jacques-bienaime-acquires-10000-shares-of-vital-therapies-inc-vtl-stock.html.

Separately, ValuEngine lowered shares of Vital Therapies from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $8.00.

Several hedge funds have recently made changes to their positions in the company. Susquehanna International Group LLP acquired a new position in shares of Vital Therapies during the 2nd quarter valued at about $268,000. Goldman Sachs Group Inc. boosted its position in shares of Vital Therapies by 261.4% during the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock valued at $676,000 after acquiring an additional 168,705 shares during the last quarter. Victory Capital Management Inc. boosted its position in shares of Vital Therapies by 1.2% during the 2nd quarter. Victory Capital Management Inc. now owns 2,579,279 shares of the company’s stock valued at $7,480,000 after acquiring an additional 29,840 shares during the last quarter. Blair William & Co. IL boosted its position in shares of Vital Therapies by 67.2% during the 2nd quarter. Blair William & Co. IL now owns 99,500 shares of the company’s stock valued at $289,000 after acquiring an additional 40,000 shares during the last quarter. Finally, LMR Partners LLP acquired a new position in shares of Vital Therapies during the 2nd quarter valued at about $396,000. 25.58% of the stock is currently owned by hedge funds and other institutional investors.

Vital Therapies Company Profile

Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.

Insider Buying and Selling by Quarter for Vital Therapies (NASDAQ:VTL)

Receive News & Stock Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related stocks with our FREE daily email newsletter.